Date: 2015-10-26
Type of information: Clinical research agreement
Compound: CPI-444 and atezolizumab (MPDL3280A)
Company: Corvus Pharmaceuticals (USA - CA) Genentech, a member of Roche Group (USA - CA - Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: clinical research
Action mechanism: immune checkpoint inhibitor/ immunotherapy product/monoclonal antibody. Anti-PDL1 antibody MPDL3280A (atezolizumab) is an investigational monoclonal antibody designed to make cancer cells more vulnerable to the body’s immune system by interfering with a protein called PD-L1. PD-L1 is found on the surface of cells in tumours and is believed to act as a “stop sign,” preventing the immune system from destroying cancer cells. By inhibiting PD-L1, MPDL3280A may enable the activation of T cells, restoring their ability to effectively detect and attack tumour cells. MPDL3280A is being studied in clinical trials to understand whether blocking PD-L1 will help the immune system respond to cancer. CPI-444 is a small molecule immune checkpoint inhibitor.
Disease: solid tumors
Details: * On October 26, 2015, Corvus Pharmaceuticals, a private clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer therapies by harnessing the immune system, announced that it entered into a clinical trial collaboration agreement with Genentech, a member of the Roche Group. The companies will collaborate on a Phase 1/1b clinical trial assessing safety, tolerability and preliminary efficacy of Corvus’ lead oral small molecule immune checkpoint inhibitor, CPI-444. The successive expansion cohort Phase 1/1b trial will examine activity of CPI-444 both as a single-agent and in combination with Genentech's investigational cancer immunotherapy atezolizumab (MPDL3280A). Atezolizumab is a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1 (PD-L1). The clinical trial is scheduled to begin in the first quarter of 2016 and will enroll patients with diverse types of solid tumors. Corvus retains global rights to CPI-444.
Financial terms:
Latest news:
